CD274 and clear cell adenocarcinoma: Nevertheless, finding immune cell PD‐L1 expression in a subset of clear cell carcinomas warrants further investigations given the approved treatment for TNBC with atezolizumab is solely based on immune cell expression of PD‐L1 (source: FDA, https://www.fda.gov/drugs/drug‐approvals‐and‐databases/fda‐approves‐atezolizumab‐pd‐l1‐positive‐unresectable‐locally‐advanced‐or‐metastatic‐triple‐negative, accessed on March 2, 2020).